-
RBC Capital on Intra-Cellular Therapies (ITCI), 'We Would Be Buyers On Weakness'
-
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
-
Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Intra-Cellular Therapies (ITCI) Prices 9.52M Share Offering at $42/sh
-
Intra-Cellular Therapies Prices Public Offering of Common Stock
-
Intra-Cellular Therapies (ITCI) Announces Proposed Stock Offering
-
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
-
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
-
Intra-Cellular Therapies to Present at the 2020 RBC Capital Markets Global Healthcare Conference
-
Intra-Cellular Therapies to Present at 2019 RBC Capital Markets Global Healthcare Conference
-
Intra-Cellular Therapies (ITCI) PT Raised to $37 at RBC Capital
-
RBC Positive on Biogen (BIIB) Karp Hire Amid Partnerships/M&A Potential
-
Biogen (BIIB) Missed Out on AveXis (AVXS) But Well-Positioned for Substantial Acquisition - RBC
-
UPDATE - Intra-Cellular Therapies to Present at RBC Capital Markets 2018 Global Healthcare Conference
-
RBC Capital Starts Intra-Cellular Therapies (ITCI) at Outperform
-
Intra-Cellular Therapies to Present at Upcoming Investor Conferences
-
Allergan pays top dollar for 'stepping stones' from neurology to dermatology
-
Intra-Cellular Therapies to Present at the 2016 RBC Capital Markets’ Healthcare Conference
-
Intra-Cellular Therapies Announces Closing of $345 Million Public Offering Including Exercise of Underwriters' Option to Purchase Additional Shares
-
Intra-Cellular Therapies Announces Closing of $345 Million Public Offering Including Exercise of Underwriters' Option to Purchase Additional Shares
-
Intra-Cellular Therapies (ITCI) Prices 6.9M Common Stock Offering at $43.50/Share
-
Intra-Cellular Therapies Prices $300 Million Public Offering of Common Stock
-
Intra-Cellular Therapies Prices $300 Million Public Offering of Common Stock
-
Intra-Cellular Therapies (ITCI) to Offer $300M in Common Stock
-
Intra-Cellular Therapies (ITCI) Commences $300M Common Stock Offering
-
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
-
RBC Capital Comments on Intra-Cellular's (ITCI) Positive ITI-007 Phase 3 Study
-
Notable Analyst Rating Changes 4/14: (PAY) (AEZS) (MDR) Upgraded; (AMTD) (SANM) (WWWW) Downgraded
-
RBC Capital Starts Intra-Cellular Therapies (ITCI) at Outperform
-
Intra-Cellular Therapies Announces Closing of $130 Million Public Offering Including Exercise of Underwriters' Option to Purchase Additional Shares
-
Intra-Cellular Therapies Announces Closing of $130 Million Public Offering Including Exercise of Underwriters' Option to Purchase Additional Shares
-
Intra-Cellular Therapies (ITCI) Prices 4.75M Offering at $24/Share
-
Intra-Cellular Therapies Prices $114 Million Public Offering of Common Stock
-
Intra-Cellular Therapies Prices $114 Million Public Offering of Common Stock
-
Intra-Cellular Therapies (ITCI) to Offer 4.25M Shares
-
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
-
Intra-Cellular Therapies to Present at the 2015 RBC Capital Markets' Healthcare Conference